Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | NR2C2 | P49116 | 2/20 | 0.66 |
| ▸ | HCK | P08631 | 1/20 | 0.66 |
| ▸ | KIT | P10721 | 2/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.61 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.61 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.61 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.61 |
| ▸ | FES | P07332 | 1/20 | 0.61 |
| ▸ | FER | P16591 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389535 | 0.96 | HTT (0.71) | HTTMAPK1ATMNR2C2HCK | |
| SCHEMBL3561769 | 0.92 | KIT (0.76) | KITEGFRBRAF | |
| SCHEMBL4250568 | 0.90 | KIT (0.61) | HTTMAPK1ATMKITEGFR | |
| SCHEMBL4249619 | 0.90 | KIT (0.63) | HTTMAPK1ATMNR2C2HCK | |
| SCHEMBL4254623 | 0.89 | HTT (0.64) | HTTMAPK1ATMNR2C2HCK | |
| SCHEMBL4254627 | 0.89 | KIT (0.79) | KITEGFRBRAF | |
| SCHEMBL30309801 | 0.87 | KIT (0.69) | HTTMAPK1ATMNR2C2HCK | |
| SCHEMBL26680109 | 0.87 | KIT (0.69) | HTTMAPK1ATMNR2C2HCK | |
| SCHEMBL4260023 | 0.87 | HTT (0.66) | HTTMAPK1ATMNR2C2HCK | |
| SCHEMBL16236899 | 0.86 | KIT (0.86) | HTTMAPK1ATMNR2C2HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | claimed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| EP-2937345-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2519517-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2519517-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2519517-A2 | TYPE II RAF KINASE INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011090738-A2 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | HTT 4679/4885MAPK1 132/4885ATM 80/4885 |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | HTT 1435/4885MAPK1 235/4885ATM 698/4885 |
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | HTT 3884/4885MAPK1 90/4885ATM 677/4885 |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | HTT 4679/4885MAPK1 132/4885ATM 80/4885 |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HTT 3884/4885MAPK1 90/4885ATM 677/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | HTT 4679/4885MAPK1 132/4885ATM 80/4885 |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HTT 3884/4885MAPK1 90/4885ATM 677/4885 |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HTT 3884/4885MAPK1 90/4885ATM 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.